Generic Teflaro Availability
Last updated on Sep 8, 2022.
TEFLARO (ceftaroline fosamil - powder;intravenous)
Approval date: October 29, 2010
Strength(s): 400MG/VIAL [RLD], 600MG/VIAL [RLD]
Has a generic version of Teflaro been approved?
No. There is currently no therapeutically equivalent version of Teflaro available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Teflaro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Phosphonocephem derivatives, process for the preparation of the same, and use thereof
Issued: July 9, 2002
Inventor(s): Tomoyasu; Ishikawa & Shohei; Hashiguchi & Yuji; Iizawa
Assignee(s): Takeda Chemical Industries, Ltd.
A novel cephem compound of the formula: wherein R1 is a phosphono group or a group convertible to a phosphono group; R2 is a hydrogen atom or a group having a linkage through a carbon atom; each of Q and X is a nitrogen atom or CH; Y is S, O or CH2; n is 0 or 1; one of R3 and R4 is a pyridinium group which may be substituted and the other is a hydrogen atom or hydrocarbon group which may be substituted, or R3 and R4 taken together may form a quaternalized nitrogen-containing heterocyclic ring which may be substituted, or its ester or its salt, which has a superior anti-bacterial activity, stability, absorbability, etc., a production thereof and a pharmaceutical composition containing it, is provided.
Patent expiration dates:
- April 11, 2022✓✓✓
- April 11, 2022
Cephem compounds useful for the treatment of bacterial infections
Issued: August 21, 2012
Inventor(s): Dedhiya; Mahendra G. & Singh; Brahma N.
The present invention relates to new cephem compounds useful for the treatment of bacterial infections of formula I: The invention also relates to methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and to methods of treatment using the compounds. The new cephem compounds are stable, exhibit good solubility, and are particularly well suited for, e.g., parenteral administration for the treatment of bacterial infections.
Patent expiration dates:
- February 10, 2031✓✓
- February 10, 2031
Compositions and methods for treating bacterial infections using ceftaroline
Issued: April 25, 2017
Assignee(s): FOREST LABORATORIES HOLDING LIMITED
The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil).
Patent expiration dates:
- September 21, 2030✓
- September 21, 2030
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- September 13, 2022 - NEW PATIENT POPULATION
More about Teflaro (ceftaroline)
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Pricing & coupons
- En español
- Drug class: next generation cephalosporins
- FDA approval history
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.